Himachal: 47 Pharma companies repeatedly fail quality tests, 19 halt production; Industry faces scrutiny
Babushahi Bureau
Tapovan (Dharamshala), November 21, 2026: Himachal Pradesh, one of India’s leading pharmaceutical manufacturing hubs, is facing serious questions over drug quality after 2,216 medicine samples manufactured in the state failed quality tests over the past three years. The government has identified 47 pharmaceutical companies whose products failed quality checks at least 10 times each, while production at 19 companies has been completely or partially halted.
The figures were shared by Health and Family Welfare Minister Colonel Dr Dhaniram Shandil in a written reply to a question raised by Bharmour MLA Dr Janak Raj during the ongoing winter session of the Himachal Pradesh Assembly.
According to the government, the 2,216 samples failed quality tests in different states and Union Territories during 2024-25, 2025-26 and up to November 1, 2026. The repeated failures involving products from the same companies have raised concerns over quality control and regulatory monitoring of pharmaceutical manufacturing units in the state.
Of the 47 companies whose products failed quality tests 10 or more times, 43 were jointly inspected by the State Drug Control Administration and the Central Drugs Standard Control Organization (CDSCO). The State Drug Controller also carried out separate inspections.
Following the inspections, the licences of three companies were completely revoked, while 19 companies were directed to stop manufacturing either fully or partially. They will not be allowed to resume the affected production until they comply with the provisions of the Drugs and Cosmetics Act, 1940, and the relevant rules.
The government also took action against individual drug products. The licences of 1,608 products were suspended, while those of 59 products were cancelled, taking the total number of products facing licensing action to 1,667. Warnings were issued to companies in four cases, and legal proceedings were initiated in 17 cases.
The government further said instructions had been issued for the recall of medicines that failed to meet prescribed quality standards to prevent their continued supply and use in the market.
As part of efforts to strengthen regulatory oversight, the government has directed drug inspectors to inspect every pharmaceutical manufacturing unit at least once a year, in accordance with the Drugs and Cosmetics Act, 1940.
MLA Dr Janak Raj had sought details of medicines manufactured in Himachal Pradesh that failed quality tests during the past three years, the action taken against the companies concerned and measures to fix accountability.
The figures are significant for Himachal Pradesh, whose pharmaceutical industry supplies medicines to markets across the country and is a major contributor to industrial activity and employment. Repeated quality failures raise concerns that extend beyond the industry’s reputation to the safety of patients who depend on these medicines.
While the government has reported action ranging from suspension and cancellation of product licences to manufacturing restrictions and legal proceedings, the key challenge remains ensuring sustained compliance and preventing substandard medicines from reaching consumers.